Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.32 |
| ▸ | GBA1 | P04062 | 4/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320893 | 0.98 | ROCK2 (0.37) | ROCK2ROCK1SLC9A5ALDH1A1HTR7 | |
| SCHEMBL6105145 | 0.95 | ROCK2 (0.35) | ROCK2ROCK1SLC9A5ALDH1A1HTR7 | |
| SCHEMBL27713565 | 0.77 | GRM4 (0.38) | ROCK2ROCK1SLC9A5ALDH1A1GRM4 | |
| SCHEMBL2317356 | 0.72 | MAPK1 (0.31) | — | |
| SCHEMBL2320475 | 0.71 | ROCK2 (0.68) | ROCK2ROCK1 | |
| SCHEMBL25027527 | 0.71 | KCNQ3 (0.35) | ROCK2ROCK1SLC9A5ALDH1A1HTR7 | |
| SCHEMBL29361363 | 0.71 | KCNQ3 (0.35) | ROCK2ROCK1SLC9A5ALDH1A1HTR7 | |
| SCHEMBL2322713 | 0.69 | GBA1 (0.41) | ALDH1A1GBA1 | |
| SCHEMBL3606370 | 0.68 | ACACB (0.41) | ALDH1A1PIK3CDKCNQ3KCNQ2AOC3 | |
| SCHEMBL3844536 | 0.67 | HCAR3 (0.40) | ROCK2ROCK1SLC9A5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ALCON, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885SLC9A5 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.